PVLA PALVELLA THERAPEUTICS INC

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA)  (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its second quarter 2025 financial results on Thursday, August 14, 2025.

Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, August 14, 2025, to discuss financial results and provide a corporate update.

To access the live webcast of the call with slides, please click or visit the "Events & Presentations" section of Palvella’s website. To access the call by phone, please use this , and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company’s website at .

About Palvella Therapeutics

Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit or follow Palvella on or (formerly known as Twitter).

QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors

Wesley H. Kaupinen

Founder and CEO, Palvella Therapeutics

Media

Marcy Nanus

Managing Partner, Trilon Advisors, LLC



EN
07/08/2025

Underlying

PVLAPALVELLA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PALVELLA THERAPEUTICS INC

 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Devel...

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients Company plans to initiate a Phase 2 trial evaluating QTORIN™ rapamycin for clinically significant angiokeratomas in the second half of 2026 ...

September 24, 2025 1 EN
 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics Announces Scientific Publication in Lymphatic Re...

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy Recent advances in understanding venous malformation disease pathogenesis highlight the PI3K/AKT/mTOR pathway as a key driver of disease proliferation, spurring real-world off-label use of systemic rapamycin (sirolimus) Publication includes a systematic review of 26 studies evaluating the use of rapamycin for the treatment of venous malformations ...

September 17, 2025 1 EN
 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of Q...

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common type of vascular malformation, with skin involvement impacting an estimated approximately 50-80% of patients, which can result in bleeding, thrombosis, ulceration, disfigurement, and proliferation QTORIN™ rapamycin has the potential to be the first approved th...

September 15, 2025 1 EN
 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics Strengthens Leadership with Appointment of Accom...

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella...

September 3, 2025 1 EN
 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics to Present at Upcoming Healthcare Investor Confe...

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at two upcoming healthcare investor conferences. The details are as follows: Cantor Global Healthcare Co...

August 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch